PTC Therapeutics Inc（PTCT）の株式分析PTCTPTC Therapeutics Inc

PTC Therapeutics, Inc. is a global biopharmaceutical company. It is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD), a rare life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its ST-920, or isaralgagene civaparvovec, is a one-time administered AAV gene therapy product candidate for the treatment of Fabry disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

PTC Therapeutics Inc is currently a hold. The stock is trading at $60.59, with a forward P/E ratio of 22.73, indicating potential for growth, but the RSI is at 39.80, suggesting it is nearing oversold territory. Analysts have mixed ratings, with targets ranging from $75 to $109, reflecting uncertainty in the stock's near-term performance. The recent acquisition of ST-920 gene therapy shows promise, but the stock has a significant year-to-date decline of 21.05%, indicating ongoing volatility. The main risk is the negative net income reported in recent quarters, with a net income of -2.81 million in Q1 2026, which raises concerns about profitability.

8 analysts cover PTCT: 2 rate it Buy, 5 Hold and 1 Sell. The average price target is 78.18.